Novo Nordisk is phasing out human insulin pens to focus on its newer diabetes and obesity medicines, sparking protests and concerns over access in low-income countries. Modern insulin, preferred in ...

Novo Nordisk is gradually ending production of human insulin pens, a spokesperson confirmed to Reuters. Instead, the company is channeling investments into manufacturing its popular obesity and ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections. The ...

“To address our current capacity constraints and reach more people with diabetes with our products in the future, our human insulin, which is currently delivered in pens and vials, will—over ...

And then there’s my insulin pen, discreet and almost painless to use. Insulin is a human right, fundamental to life. Yet, paradoxically, it is more accessible to some than to others. For those ...

A doctor and honorary researcher at the University of Exeter is leading a campaign to make reusable insulin pens the standard for treating diabetes patients. Dr Vincent Simpson aims to cut down on ...

The introduction of smart insulin pens, which represent a substantial development in the technology currently used to control diabetes, may benefit patients who are reliant on insulin by enhancing ...

"What students can read in schools provides the foundation for their lives," says PEN America Eric Charbonneau/Getty; Lou Rocco/ABC via Getty; VALERIE MACON/AFP via Getty Book bans are sharply on ...

Novo said last year it would pull its Levemir insulin from the U.S. market at the end of 2024, months after cutting its price by 65% to $108 a vial and $162 for a 5-pack of injector pens.

Novo said last year it would pull its Levemir insulin from the U.S. market at the end of 2024, months after cutting its price by 65% to $108 a vial and $162 for a 5-pack of injector pens.